Tirbanibulin 1% real‐world use in 679 actinic keratoses patients during warm season (SUMM‐AK study)

Carugno, A.;Nazzaro, G.;Argnani, L.;Bellinato, F.;Zappia, E.;Masala, M. V.;Dal Bello, G.;Valenti, M.;Addari, G.

Data Curation

;Ciccarese, G.;Bruni, M.;Trovato, E.;Paolino, G.;Balestri, R.;D'Arino, A.;Magnoni, C.;Zavattaro, E.;Toni, G.;Giuffrida, R.;Verdelli, A.;Caccavale, S.;Villani, A.;Giacalone, S.;Recalcati, S.;Barruscotti, S.;Bighetti, S.;Bettolini, L.;Fiorillo, G.;Germi, L.;Fazio, S.;Infusino, S. D.;Eibenschutz, L.;Cesari, A.;Dragotto, M.;Zolo, G. B. M.;Savoia, P.;Zalaudek, I.;Sala, E.;Errichetti, E.;Mercuri, S. R.;Esposito, M.;Foti, C.;Atzori, L.

Writing - Review & Editing

;Ardigò, M.;Danese, P.;Ribero, S.;Gisondi, P.;Marzano, A. V.;Zerbinati, N.

2025-01-01

---

Abstract

Tirbanibulin 1% ointment represents an effective, well-tolerated and innovative field therapy for AK, with a short regimen that fosters adherence and maintains safety even during periods of high UV exposure. The results of this cohort multicenter Italian study endorse tirbanibulin as a compelling therapeutic option throughout the year, including the warmer months. Future prospective studies should further refine follow-up protocols and evaluate the long-term durability of clinical response.